Fluidiconic Biotechnology

Fluidiconic Biotechnology is a Taiwan-based biotech company specializing in precision oncology through its proprietary MedSelect platform, which leverages advanced tumor-on-a-chip and microfluidics technologies. The MedSelect system enables pharmaceutical companies and CROs to perform ex vivo drug efficacy evaluations using patient-derived tumor cells. This approach closely simulates the complex human tumor microenvironment—including immune cell interactions, physiological gradients, desmoplasia, angiogenesis, and dynamic drug concentration changes—to predict therapeutic efficacy and resistance more accurately. Fluidiconic offers collaborative R&D services as a CRO/CDMO partner for pharma clients seeking to accelerate preclinical development or optimize treatment strategies.